PPARα agonists, such as bezafibrate and a novel drug MHY2013, can significantly increase the expression of FGF21 for alleviating obesity-induced insulin resistance, dyslipidemia and hepatic steatosis (An et al., 2017). Here, FGF21 is linked to obesity disorder.